[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571767":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":17,"locations":24,"responsibleParty":40,"collaborators":43,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":7,"enrollmentInfo":59,"targetDuration":7,"studyType":62,"phases":7,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":27,"whyStopped":7,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"University of Turin, Italy","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"non interventional study with the use of biological samples.","Patients will undergo to the follow evaluations:\n\nGut microbiome on stool samples by NGS (16S rRNA gene amplicon sequencing); Markers of impaired intestinal permeability \\[diaminoxidase (DAO), serum zonulin\\], and markers of inflammation of the GI tract (fecal calprotectin); Plasma inflammatory indices, cytokines (by Luminex), markers of autoimmunity, and metabolic profile; Acquired and adaptive immunity by multiparametric flow cytometry on PB samples.",[13],{"name":14,"affiliation":15,"role":16},"Carmen Fava","Department of Clinical and Biological Sciences, University of Turin, Turin, Italy","PRINCIPAL_INVESTIGATOR",[18,22],{"name":14,"role":19,"phone":20,"phoneExt":7,"email":21},"CONTACT","00390115082224","carmen.fava@unito.it",{"name":23,"role":19,"phone":20,"phoneExt":7,"email":7},"Valentina Bonuomo",[25],{"facility":26,"status":27,"city":28,"state":7,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"AO Ordine Mauriziano di Torino","RECRUITING","Torino","10128","Italy","IT",{"type":33,"coordinates":34},"Point",[35,36],11.99138,44.88856,{"lat":36,"lon":35},[39],{"name":14,"role":19,"phone":20,"phoneExt":7,"email":21},{"type":41,"investigatorFullName":14,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Professor",[44,47],{"name":45,"class":46},"Pfizer","INDUSTRY",{"name":48,"class":46},"Novartis","100571767","interaction-between-gut-microbiota-and-tkis-in-defining-the-clinical-outcomes-of-patients-with-cml-100571767",false,"NCT06724536","Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML","Interaction Between Gut Microbiota and Tyrosine Kinase Inhibitors in Defining the Clinical Outcomes of Patients With Chronic Myeloid Leukemia","MICROBIO-LMC","Inclusion Criteria:\n\n* Age \\> 18 years old\n* Chronic Myeloid Leukemia Patients\n* Any stage of the disease\n\nExclusioni Criteria:\n\nnone","ALL","18 Years",{"count":60,"type":61},100,"ESTIMATED","OBSERVATIONAL","Gut microbiome (GM) is acquiring increasing importance in human health and disease. GM influences hematopoiesis and immune cells types differentiation. Patients with cancer are characterized by dysbiosis and compromised immunity. In the case of Chronic Myeloid Leukemia (CML), treatment with Tyrosine Kinase Inhibitors (TKIs) restores immunosurveillance; in particular deep molecular response (DMR) is associated with increased levels of NK and CD8+ Tcells. There is no literature on the effects of GM on CML outcomes. This project aims to identify a microbial signature associated with a higher probability of achieving DMR.",[65],"Leukemia,Myeloid, Chronic",[67,68,69,70],"chronic myeloid leukemia","gut","microbiota","tyrosine kinase inhibitors","2024-12-04",{"date":73,"type":74},"2024-12-09","ACTUAL",{"date":76,"type":74},"2022-10-01",{"date":78,"type":61},"2026-10-01",{"name":14,"class":6},1]